Skip to main content

Articles

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

Infectious Diseases

Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer

Oncology Overview, Oncology

NCCN Guidelines Update: Initial Colorectal Screening Lowered to Age 45

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Interview with the Innovators

Genmab Is Developing a World-Class Antibody Portfolio with the Hope to Bring the Right Cancer Therapy for the Right Patient

A Sylvatic or Syncretic Approach to Healthcare Innovation?

David B. Nash, MD, MBA

Review Article, Biosimilars, Practice Management

Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward

Raymond K. Cross, MD, MS; Amy L. Stewart, MSN, RN, FNP-C; Colin C. Edgerton, MD, FACP, FACR, RhMSUS; Bhavesh Shah, RPh, BCOP; John A. Welz, MPH; Jonathan Kay, MD

Page 15 of 244
Results 141 - 150 of 2440